An intranasal ASO therapeutic targeting SARS-CoV-2

An intranasal ASO therapeutic targeting SARS-CoV-2

Despite approved vaccines and anti-virals to prevent and treat SARS-CoV-2 infection, there is a need for further development of efficient antiviral therapeutic strategy. Here, Zhu et al. develop locked nucleic acid antisense oligonucleotides (LNA ASOs) targeting the 5’ leader sequence of SARS-CoV-2...

Full description

Bibliographic Details
Main Authors: Chi Zhu, Justin Y. Lee, Jia Z. Woo, Lei Xu, Xammy Nguyenla, Livia H. Yamashiro, Fei Ji, Scott B. Biering, Erik Van Dis, Federico Gonzalez, Douglas Fox, Eddie Wehri, Arjun Rustagi, Benjamin A. Pinsky, Julia Schaletzky, Catherine A. Blish, Charles Chiu, Eva Harris, Ruslan I. Sadreyev, Sarah Stanley, Sakari Kauppinen, Silvi Rouskin, Anders M. Näär
Format: Article
Language:English
Published: Nature Portfolio 2022-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-32216-0

Internet

https://doi.org/10.1038/s41467-022-32216-0

Similar Items